Market Research Logo

Clostridium difficile Infections - Pipeline Review, H1 2017

Introduction
Global Markets Direct Report Coverage 8
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Overview 9
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 20
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development 29
Absynth Biologics Ltd 29
Actelion Ltd 29
AIMM Therapeutics BV 30
Akthelia Pharmaceuticals Ltd 30
AmpliPhi Biosciences Corp 31
Appili Therapeutics 31
Assembly Biosciences Inc 32
AvidBiotics Corp 32
C3J Therapeutics Inc 33
CaroGen Corp 33
Crestone Inc 34
Da Volterra SAS 34
Daiichi Sankyo Company Ltd 35
Evec Inc 35
GangaGen Inc 36
ImmunoBiology Ltd 36
Immuron Ltd 37
Inovio Pharmaceuticals Inc 37
Integrated BioTherapeutics Inc 38
Merck & Co Inc 38
MGB Biopharma Ltd 39
Microbiotix Inc 39
Micropharm Ltd 40
Miyarisan Pharmaceutical Company Ltd 40
Nabriva Therapeutics AG 41
Nanotherapeutics Inc 41
Novabiotics Ltd 42
NovoBiotic Pharmaceuticals LLC 42
Oragenics Inc 43
Otsuka Holdings Co Ltd 43
Pfizer Inc 44
Prokarium Ltd 44
Rebiotix Inc 45
Sanofi Pasteur SA 45
Second Genome Inc 46
Seres Therapeutics Inc 46
Serometrix LLC 47
Sorrento Therapeutics Inc 47
Summit Therapeutics Plc 48
Synthetic Biologics Inc 48
Valevia UK Ltd 49
Valneva SE 49
XBiotech Inc 50
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles 51
ABCD-01 - Drug Profile 51
ABIM-101 - Drug Profile 53
AKT-10081 - Drug Profile 54
Antibodies for Enterocolitis - Drug Profile 55
Antibodies to Inhibit Toxin A and Toxin B for Clostridium difficile Infections - Drug Profile 56
AvR2-V10 - Drug Profile 57
Biologic for Clostridium difficile Infections - Drug Profile 59
Biologics for Clostridium Difficile Infections - Drug Profile 60
cadazolid - Drug Profile 61
CBM-588 - Drug Profile 63
CD-17DL - Drug Profile 65
Cdiff Snare - Drug Profile 66
clofazimine - Drug Profile 67
Clostridium difficile (virus like particle) vaccine - Drug Profile 68
Clostridium difficile vaccine - Drug Profile 69
Clostridium difficile vaccine - Drug Profile 71
Clostridium difficile vaccine - Drug Profile 72
Clostridium difficile vaccine - Drug Profile 73
clostridium difficile vaccine - Drug Profile 75
Clostridium difficile vaccine - Drug Profile 76
Clostridium difficile vaccine - Drug Profile 77
Clostridium difficile vaccine - Drug Profile 78
Clostridium difficile vaccine - Drug Profile 79
Clostridium difficile vaccine - Drug Profile 80
CP-101 - Drug Profile 81
CRS-3123 - Drug Profile 82
DAV-132 - Drug Profile 83
DiffiKil - Drug Profile 84
Drugs for Clostridium difficile Infections - Drug Profile 85
DS-2969 - Drug Profile 86
EV-029104 - Drug Profile 87
EV-029105A - Drug Profile 88
fidaxomicin - Drug Profile 89
FIN-403 - Drug Profile 96
IMM-529 - Drug Profile 97
INS-5010 - Drug Profile 98
MBX-500 - Drug Profile 99
MCB-3681 - Drug Profile 101
MCB-3837 - Drug Profile 102
metronidazole - Drug Profile 103
MGBBP-3 - Drug Profile 104
Monoclonal Antibodies for Clostridium difficile Infections - Drug Profile 107
Monoclonal Antibodies to Inhibit TcdA and TcdB for Clostridium Difficile and Staphylococcus Aureus Infections - Drug Profile 108
Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile 109
Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile 110
Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile 111
NP-432 - Drug Profile 112
OG-253 - Drug Profile 113
OG-716 - Drug Profile 115
OPS-2071 - Drug Profile 116
OraCAb - Drug Profile 117
P-100031 - Drug Profile 118
P-4A - Drug Profile 119
PF-06425090 - Drug Profile 120
PolyCAb - Drug Profile 122
Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile 123
ramoplanin - Drug Profile 124
RBX-2660 - Drug Profile 125
RBX-7455 - Drug Profile 128
ribaxamase - Drug Profile 129
ridinilazole - Drug Profile 135
SER-109 - Drug Profile 141
SER-262 - Drug Profile 145
SHP-01 - Drug Profile 146
Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections - Drug Profile 147
Small Molecules for Clostridium Difficile Infections - Drug Profile 148
Small Molecules for Clostridium Difficile Infections - Drug Profile 149
Small Molecules for Clostridium difficile Infections - Drug Profile 150
Small Molecules to Inhibit 23S rRNA for Clostridium difficile and Helicobacter pylori Infections - Drug Profile 151
Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile 152
Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile 153
Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections - Drug Profile 154
Small Molecules to Inhibit Metalloprotease for Clostridium difficile Infections - Drug Profile 155
Small Molecules to Inhibit Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile 156
SQ-641 - Drug Profile 157
SYN-006 - Drug Profile 159
SYN-007 - Drug Profile 160
TNP-2092 - Drug Profile 161
VAL-301 - Drug Profile 162
VE-303 - Drug Profile 163
VLA-84 - Drug Profile 164
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects 167
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products 170
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones 171
Featured News & Press Releases 171
Appendix 182
Methodology 182
Coverage 182
Secondary Research 182
Primary Research 182
Expert Panel Validation 182
Contact Us 182
Disclaimer 183
List of Tables
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Actelion Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AIMM Therapeutics BV, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corp, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Assembly Biosciences Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AvidBiotics Corp, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by C3J Therapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by CaroGen Corp, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Crestone Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Da Volterra SAS, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evec Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by GangaGen Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmunoBiology Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immuron Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Integrated BioTherapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Merck & Co Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MGB Biopharma Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Microbiotix Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Micropharm Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nabriva Therapeutics AG, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nanotherapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Novabiotics Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Oragenics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Otsuka Holdings Co Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Pfizer Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Prokarium Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Rebiotix Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Second Genome Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Seres Therapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Serometrix LLC, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sorrento Therapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Synthetic Biologics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valevia UK Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valneva SE, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by XBiotech Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Clostridium difficile Infections - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections - Pipeline Review, H1 2017, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 11, 29, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 7 molecules, respectively.

Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Clostridium difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Clostridium difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Clostridium difficile Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Clostridium difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;